Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heinz Hartmann

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pain|April 1, 1995
Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetronHarald Schwörer, Heinz Hartmann, Giuliano Ramadori
Scandinavian Journal of Gastroenterology|February 18, 2006
Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replicationOliver Schildgen, Heinz Hartmann, Wolfram H Gerlich
Zeitschrift Fur Gastroenterologie|November 9, 2020
[Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase in Germany]Dietrich Hüppe, Claus Niederau, Yvonne Serfert, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary CirrhosisCorinna Hopf, Renate Grieshaber, Heinz Hartmann, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 13, 2016
[Inflammatory Bowel Disease Competence Network]Stefan Schreiber, Heinz Hartmann, Wolfgang Kruis, et al.
BMC Gastroenterology|July 10, 2020
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart reviewUlf Helwig, Michael Mross, Stefan Schubert, et al.
The New England Journal of Medicine|April 28, 2006
Variant of hepatitis B virus with primary resistance to adefovirOliver Schildgen, Hueseyin Sirma, Anneke Funk, et al.
European Journal of Gastroenterology & Hepatology|July 14, 2020
Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry studyMaria M Gabriel, Gerald Kircheis, Svenja Hardtke, et al.
Digestive Diseases and Sciences|November 19, 2015
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in GermanyJörg Petersen, Renate Heyne, Stefan Mauss, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pain|April 1, 1995
Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetronHarald Schwörer, Heinz Hartmann, Giuliano Ramadori
Scandinavian Journal of Gastroenterology|February 18, 2006
Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replicationOliver Schildgen, Heinz Hartmann, Wolfram H Gerlich
Zeitschrift Fur Gastroenterologie|November 9, 2020
[Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase in Germany]Dietrich Hüppe, Claus Niederau, Yvonne Serfert, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary CirrhosisCorinna Hopf, Renate Grieshaber, Heinz Hartmann, et al.
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|March 13, 2016
[Inflammatory Bowel Disease Competence Network]Stefan Schreiber, Heinz Hartmann, Wolfgang Kruis, et al.
BMC Gastroenterology|July 10, 2020
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart reviewUlf Helwig, Michael Mross, Stefan Schubert, et al.
The New England Journal of Medicine|April 28, 2006
Variant of hepatitis B virus with primary resistance to adefovirOliver Schildgen, Hueseyin Sirma, Anneke Funk, et al.
European Journal of Gastroenterology & Hepatology|July 14, 2020
Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry studyMaria M Gabriel, Gerald Kircheis, Svenja Hardtke, et al.
Digestive Diseases and Sciences|November 19, 2015
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in GermanyJörg Petersen, Renate Heyne, Stefan Mauss, et al.
The Lancet. Gastroenterology & Hepatology|August 19, 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Pol F Boudes, Mark G Swain, et al.
Pageof 1